Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study.
Stenotrophomonas maltophilia
cohort study
combination therapy
monotherapy
treatment
Journal
Expert review of anti-infective therapy
ISSN: 1744-8336
Titre abrégé: Expert Rev Anti Infect Ther
Pays: England
ID NLM: 101181284
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78). Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.
Sections du résumé
BACKGROUND
UNASSIGNED
The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by
METHODS
UNASSIGNED
This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by
RESULTS
UNASSIGNED
A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78).
CONCLUSION
UNASSIGNED
Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.
Identifiants
pubmed: 38738566
doi: 10.1080/14787210.2024.2353704
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM